Multi-Omics Analysis of Gut Microbiota in Inflammatory Bowel Diseases: What Benefits for Diagnostic, Prognostic and Therapeutic Tools?

Inflammatory bowel diseases (IBDs), which include Crohn's disease and ulcerative colitis, are multifactorial diseases that involve in particular a modification of the gut microbiota, known as dysbiosis. The initial sets of metataxonomic and metagenomic data first made it possible to approximate the microbiota profile in IBD. In addition, today the new 'omics' techniques have enabled us to draw up a functional and integrative map of the microbiota. The key concern in IBD is to develop biomarkers that allow us to assess the activity of the disease and predict the complications and progression, while also guiding the therapeutic care so as to develop personalized medicine. In this review, we present all of the latest discoveries on the microbiota provided by omics and we outline the benefits of these techniques in developing new diagnostic, prognostic and therapeutic tools.

Automated summary

Inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis are complex diseases involving gut microbiota dysbiosis. By incorporating the functional and integrative map of microbiota, researchers aim to develop personalized medicine and enhance the application of new diagnostic, prognostic, and therapeutic tools.